PMC:7243768 / 66219-67167 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2593","span":{"begin":906,"end":910},"obj":"Gene"},{"id":"2594","span":{"begin":68,"end":88},"obj":"Species"},{"id":"2595","span":{"begin":162,"end":172},"obj":"Species"},{"id":"2596","span":{"begin":573,"end":583},"obj":"Species"},{"id":"2597","span":{"begin":62,"end":66},"obj":"Disease"},{"id":"2598","span":{"begin":148,"end":156},"obj":"Disease"},{"id":"2599","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"2600","span":{"begin":283,"end":292},"obj":"Disease"},{"id":"2601","span":{"begin":559,"end":567},"obj":"Disease"},{"id":"2602","span":{"begin":755,"end":770},"obj":"Disease"},{"id":"2603","span":{"begin":867,"end":882},"obj":"Disease"}],"attributes":[{"id":"A2593","pred":"tao:has_database_id","subj":"2593","obj":"Gene:59272"},{"id":"A2594","pred":"tao:has_database_id","subj":"2594","obj":"Tax:9534"},{"id":"A2595","pred":"tao:has_database_id","subj":"2595","obj":"Tax:2697049"},{"id":"A2596","pred":"tao:has_database_id","subj":"2596","obj":"Tax:2697049"},{"id":"A2597","pred":"tao:has_database_id","subj":"2597","obj":"MESH:D012128"},{"id":"A2598","pred":"tao:has_database_id","subj":"2598","obj":"MESH:D007239"},{"id":"A2599","pred":"tao:has_database_id","subj":"2599","obj":"MESH:D007239"},{"id":"A2600","pred":"tao:has_database_id","subj":"2600","obj":"MESH:D007239"},{"id":"A2601","pred":"tao:has_database_id","subj":"2601","obj":"MESH:D007239"},{"id":"A2602","pred":"tao:has_database_id","subj":"2602","obj":"MESH:C000657245"},{"id":"A2603","pred":"tao:has_database_id","subj":"2603","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T536","span":{"begin":89,"end":95},"obj":"Body_part"},{"id":"T537","span":{"begin":104,"end":108},"obj":"Body_part"},{"id":"T538","span":{"begin":454,"end":474},"obj":"Body_part"},{"id":"T539","span":{"begin":469,"end":474},"obj":"Body_part"},{"id":"T540","span":{"begin":483,"end":489},"obj":"Body_part"},{"id":"T541","span":{"begin":530,"end":535},"obj":"Body_part"},{"id":"T542","span":{"begin":739,"end":744},"obj":"Body_part"},{"id":"T543","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A536","pred":"fma_id","subj":"T536","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A537","pred":"fma_id","subj":"T537","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A538","pred":"fma_id","subj":"T538","obj":"http://purl.org/sig/ont/fma/fma82841"},{"id":"A539","pred":"fma_id","subj":"T539","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A540","pred":"fma_id","subj":"T540","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A541","pred":"fma_id","subj":"T541","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A542","pred":"fma_id","subj":"T542","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A543","pred":"fma_id","subj":"T543","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T264","span":{"begin":89,"end":95},"obj":"Body_part"},{"id":"T265","span":{"begin":483,"end":489},"obj":"Body_part"},{"id":"T266","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A264","pred":"uberon_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A265","pred":"uberon_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A266","pred":"uberon_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T789","span":{"begin":62,"end":66},"obj":"Disease"},{"id":"T790","span":{"begin":162,"end":170},"obj":"Disease"},{"id":"T791","span":{"begin":162,"end":166},"obj":"Disease"},{"id":"T792","span":{"begin":283,"end":303},"obj":"Disease"},{"id":"T793","span":{"begin":283,"end":292},"obj":"Disease"},{"id":"T794","span":{"begin":573,"end":581},"obj":"Disease"},{"id":"T795","span":{"begin":573,"end":577},"obj":"Disease"},{"id":"T796","span":{"begin":750,"end":758},"obj":"Disease"},{"id":"T797","span":{"begin":750,"end":754},"obj":"Disease"},{"id":"T798","span":{"begin":761,"end":770},"obj":"Disease"},{"id":"T799","span":{"begin":867,"end":882},"obj":"Disease"},{"id":"T800","span":{"begin":873,"end":882},"obj":"Disease"}],"attributes":[{"id":"A789","pred":"mondo_id","subj":"T789","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A790","pred":"mondo_id","subj":"T790","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A791","pred":"mondo_id","subj":"T791","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A792","pred":"mondo_id","subj":"T792","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A793","pred":"mondo_id","subj":"T793","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A794","pred":"mondo_id","subj":"T794","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A795","pred":"mondo_id","subj":"T795","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A796","pred":"mondo_id","subj":"T796","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A797","pred":"mondo_id","subj":"T797","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A798","pred":"mondo_id","subj":"T798","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A799","pred":"mondo_id","subj":"T799","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A800","pred":"mondo_id","subj":"T800","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T818","span":{"begin":19,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T819","span":{"begin":40,"end":41},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T820","span":{"begin":82,"end":88},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9479"},{"id":"T821","span":{"begin":89,"end":95},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T822","span":{"begin":89,"end":95},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T823","span":{"begin":89,"end":95},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T824","span":{"begin":104,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T825","span":{"begin":123,"end":127},"obj":"http://purl.obolibrary.org/obo/CLO_0009524"},{"id":"T826","span":{"begin":123,"end":127},"obj":"http://purl.obolibrary.org/obo/CLO_0050515"},{"id":"T827","span":{"begin":345,"end":346},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T828","span":{"begin":464,"end":474},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T829","span":{"begin":483,"end":489},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T830","span":{"begin":483,"end":489},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T831","span":{"begin":483,"end":489},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T832","span":{"begin":530,"end":535},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T833","span":{"begin":629,"end":630},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T834","span":{"begin":739,"end":744},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T835","span":{"begin":821,"end":822},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T836","span":{"begin":922,"end":927},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T837","span":{"begin":922,"end":927},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T142","span":{"begin":298,"end":315},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T143","span":{"begin":298,"end":315},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T144","span":{"begin":608,"end":625},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T145","span":{"begin":608,"end":625},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T146","span":{"begin":867,"end":882},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"LitCovid-sentences","denotations":[{"id":"T489","span":{"begin":0,"end":67},"obj":"Sentence"},{"id":"T490","span":{"begin":68,"end":173},"obj":"Sentence"},{"id":"T491","span":{"begin":174,"end":272},"obj":"Sentence"},{"id":"T492","span":{"begin":273,"end":422},"obj":"Sentence"},{"id":"T493","span":{"begin":423,"end":653},"obj":"Sentence"},{"id":"T494","span":{"begin":654,"end":781},"obj":"Sentence"},{"id":"T495","span":{"begin":782,"end":948},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

{"project":"2_test","denotations":[{"id":"32450165-32354636-66451129","span":{"begin":772,"end":775},"obj":"32354636"},{"id":"32450165-17482553-66451130","span":{"begin":776,"end":779},"obj":"17482553"}],"text":"Currently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}